Jingyao Wang

Jingyao Wang

Auto-generated profile, based on publicly available information

Jingyao Wang

Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics Peking University Shenzhen Hospital Shenzhen China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JQJing Quan
Jing Quan
XPXiang Pan
Xiang Pan
YLYawen Li
Yawen Li
YHYimin Hu
Yimin Hu
LTLingzhi Tao
Lingzhi Tao
YLYongqing Lai
Yongqing Lai
Renal cell carcinoma (RCC) is a most common kidney malignancy, with atypical symptoms in the early stage and poor outcome in the late stage. Recently, emerging evidence revealed that some miRNAs play an essential role in the tumorigenesis and progression of RCC. Therefore, the aim of this study is that understand the detailed molecular mechanism of miR-23a-3p in RCC and identify its potential clinical value. In this study, RT-qPCR, wound scratch assay, cell proliferation assay, transwell assay and flow cytometry assay were performed to detect miR-23a-3p expression and its proliferation, migration and apoptosis in RCC. The bioinformatics analysis, RT-qPCR, western blot and luciferase reporter assay were performed to discern and examine the relationship between miR-23a-3p and its potential targets. Moreover, we analyzed the relationship between miR-23a-3p expression and clinicopathological variables or overall survival (OS) from 118 formalin-fixed paraffin-embedded RCC samples. miR-23a-3p is significantly up-regulated in RCC tissue samples, RCC cell lines and the TCGA database. Upregulating miR-23a-3p enhances, while silencing miR-23a-3p suppresses cell viability, proliferation and mobility in ACHN and 786-O cell lines. Besides, overexpression of miR-23a-3p inhibits the cell apoptosis. Then our study further reveals that miR-23a-3p regulates tumorigenesis by targeting Proline-Rich Nuclear Receptor Coactivator 2 (PNRC2). Also, the cox proportional hazard regression analysis indicates that low expression of miR-23a-3p patients has a remarkable longer OS. Our results reveals that miR-23a-3p may not only serve as a new biomarker for prognosis but also serve as a new therapeutic strategy in the RCC treatment.

1 October 2020 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Closed access
MLMengxue Lu
Mengxue Lu
SDShuren Ding
Shuren Ding
JWJingyao Wang
Jingyao Wang
YLYue Liu
Yue Liu
ZAZhen An
Zhen An
JSJack Song
Jack Song

5 August 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
JWJingyao Wang
Jingyao Wang
LZLiwen Zhao
Liwen Zhao
XPXiqi Peng
Xiqi Peng
KLKaihao Liu
Kaihao Liu
CZChunduo Zhang
Chunduo Zhang
YLYongqing Lai
Yongqing Lai
Objective: Previous research has shown that the miR‐130 family is closely related to the occurrence and development of bladder cancer. We hope to use the miR‐130 family members as new, non‐invasive, and easily detectable biomarkers for bladder cancer.Methods: We analyzed 428 cases in The Cancer Genome Atlas‐Bladder Urothelial Carcinoma database and verified that the miR‐130 family members were significantly overexpressed in bladder cancer. A total of 74 bladder cancer patients and 90 controls were enrolled. The relative expression of the miR‐130 family in serum was detected using quantitative reverse transcription‐polymerase chain reaction. The diagnostic efficacy of the miR‐130 family members was determined using the receiver operating characteristic method (ROC), and a diagnostic panel was built using logistic regression. The results of the study were further confirmed in an external validation set of 492 samples from the Gene Expression Omnibus database.Results: The expression of the miR‐130 family members (except for miR‐301b‐3p) in the serum of bladder cancer patients was higher than that in the controls. The diagnostic capabilities for bladder cancer were 0.847 (miR‐130a‐3p), 0.762 (miR‐130b‐3p), and 0.892 (miR‐301a‐3p). We established a three‐miRNA panel with an area under the ROC curve as high as 0.961, indicating that it is a promising clinical diagnostic biomarker of bladder cancer with high sensitivity and specificity.Conclusion: The expression levels of miR‐130 family members in serum can effectively distinguish the bladder cancer patients from healthy controls. This finding will facilitate the clinical diagnosis of bladder cancer.

28 November 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
CZChunduo Zhang
Chunduo Zhang
XPXiang Pan
Xiang Pan
XPXiqi Peng
Xiqi Peng
KLKaihao Liu
Kaihao Liu
JWJingyao Wang
Jingyao Wang
YLYongqing Lai
Yongqing Lai
The diagnosis of renal cell carcinoma (RCC) is often made late since there is no early symptom, which thus results in dismal patient prognosis. As a result, new biomarkers are urgently needed and efforts should be made to identify their functions in predicting RCC prognosis. microRNAs (miRNAs) are a class of small noncoding RNAs that are about 20‐22 nucleotides in length, and they have been demonstrated to function as prognostic markers in numerous tumors. This study aimed to assess the role of miR‐30b‐5p in predicting the prognosis of RCC postoperatively. In this study, RNA was extracted from 284 formalin‐fixed and paraffin‐embedded kidney cancer tissue samples. After cDNA synthesis, real‐time quantitative PCR (RT‐qPCR) was adopted for detecting the relative miR‐30b‐5p level. Then, the Kaplan‐Meier method, Cox regression analysis, and the receiver operating characteristic curve analysis were applied in analyzing the miR‐30b‐5p effect on the prognosis for patients. Our findings indicated that, following adjustment for age, gender, tumor stage, and tumor size, patients with low miR‐30b‐5p expression had remarkably longer overall survival. Thus, the miR‐30b‐5p level might be related to RCC prognosis.

13 January 2022 in PPAR Research
Verified
Journal Article
Open access
PDF file
MTMinghui Tang
Minghui Tang
JWJingyao Wang
Jingyao Wang
LFLiangsheng Fan
Liangsheng Fan
Endometrial cancer is a common malignant tumor in gynecology, and the prognosis of advanced patients is dismal. Recently, many studies on the peroxisome proliferator-activated receptor pathway have elucidated its crucial involvement in endometrial cancer. Copy number variation (CNA) and nucleotide mutations often occur in tumor tissues, leading to abnormal protein expression and changes in protein structure. We analyzed the exon sequencing data of endometrial cancer patients in the TCGA database and found that somatic changes in PPAR pathway-related genes (PPAR-related-gene) often occur in UCEC patients. Patients with CNA or mutation changes in the exon region of the PPAR-related-gene usually have different prognostic outcomes. Furthermore, we found that the mRNA transcription and protein translation levels of PPAR-related-gene in UCEC are significantly different from that of adjacent tissues/normal uterus. The transcription level of some PPAR-related-gene (DBI, CPT1A, CYP27A1, and ME1) is significantly linked to the prognosis of UCEC patients. We further constructed a prognostic predicting tool called PPAR Risk score, a prognostic prediction tool that is a strong independent risk factor for the overall survival rate of UCEC patients. Comparing to the typical TNM classification system, this tool has higher prediction accuracy. We created a nomogram by combining PPAR Risk score with clinical characteristics of patients in order to increase prediction accuracy and promote clinical use. In summary, our study demonstrated that PPAR-related-gene in UCEC had significant alterations in CNA, nucleotide mutations, and mRNA transcription levels. These findings can provide a fresh perspective for postoperative survival prediction and individualized therapy of UCEC patients.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
WCWeifeng Chen
Weifeng Chen
JWJingyao Wang
Jingyao Wang
QZQiumei Zhao
Qiumei Zhao
DLDandan Liu
Dandan Liu
DSDonglin Sun
Donglin Sun
XZXiaoren Zhang
Xiaoren Zhang
Due to high energy and material metabolism requirements, mitochondria are frequently active in tumor cells. Our study found that the high energy metabolism status is positively correlated with the poor prognosis of patients with lung adenocarcinoma. We constructed a scoring system (mitoRiskscore) based on the gene expression of specific mitochondrial localized proteins through univariate and LASSO cox regression. It has been shown that high mitoRiskscore was correlated with a shorter survival time after surgery in patients with lung adenocarcinoma. Compared with the typical TNM grading system, the mitoRiskscore gene panel had higher prediction accuracy. A vast number of external verification results ensured its universality. Additionally, the mitoRiskscore could evaluate the metabolic pattern and chemotherapy sensitivity of the tumor samples. Lung adenocarcinoma with higher mitoRiskscore was more active in glycolysis, and oxidative phosphorylation expression of proliferation‐related pathway genes was also significantly upregulated. In contrast, patients with low mitoRiskscore had similar metabolic patterns to normal tissues. In order to improve the accuracy of prediction ability and promote clinical usage, we developed a nomogram that combined mitoRiskscore and clinical prognostic factors to predict the 3‐year, 5‐year, and 10‐year survival rates of patients. We also performed in vitro experiments to verify the function of the key genes in the mitoRiskscore panel. In conclusion, the mitoRiskscore scoring system may assist clinicians to judge the postoperative survival rate and chemotherapy of patients with lung adenocarcinoma.